Clinical Trials

A4001067

Sponsor:
Pfizer

Study Title:
An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients (POEM)

Summary:
The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Phase:
Phase 4

Study Design:
Observational Cohort Prospective

Eligibility Criteria:

• Ages Eligible for Study:18 Years and older
• Genders Eligible for Study:Both
• Accepts Healthy Volunteers:No
• Sampling Method:Non-Probability Sample

Study Population Treatment experienced, HIV-1 infected patients in routine clinical practice.

Drugs/Treatment Provided:
Groups/Cohorts: Maraviroc exposed Drug: Maraviroc along with an optimized background antiretroviral drug regimen Maraviroc prescribed per approved local label.

Groups/Cohorts: Maraviroc Drug: Optimized background antiretroviral drug regimen without maraviroc v

Compensation:
To be determined

Study Duration: Up to 5 years

Principal Investigator: Donna Mildvan, M.D.

Study Location: Beth Israel Medical Center

Infectious Diseases/AIDS Clinical Trials Unit

350 East 17th Street, 3rd floor

New York, NY, 10003

Contact Information: Phone: 212-420-4519 or 800-483-7339 Email

ALL TRIALS IN THIS CATEGORY

Click highlighted ID code below to view individual trial details.

GS-0144
NO LONGER RECRUITING: A Multicenter, Randomized, Double-Blind, Double-Dummy, Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults

A4001067
An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients (POEM)

TRIALS AT A GLANCE

JOIN A CLINICAL TRIAL